Home | By sponsor

CENTER OF MOLECULAR IMMUNOLOGY

Trials shown by sponsor

Public title Date of Registration State
Itolizumab-Plasmapheresis in patients with COVID-19 30/06/2021 Registered
Nimotuzumab inoperable esophageal epithelial tumors, Phase IV 30/06/2016 Registered
Combined NGcGM3/VSSP and Nimotuzumab in advanced non-small cell lung cancer (NSCLC) 30/04/2018 Registered
Nimotuzumab-pancreatic cancer-adults-Phase IV. 30/04/2017 Registered
Predictor of response with CIMAvax EGF© in NSCLC Phase III 29/01/2016 Registered
Nimotuzumab in Non-Small Cell Lung Cancer (NSCLC) of inoperable stage III epidermoid histology, concomitant with Chemo and Radiotherapy (CRT) 28/12/2018 Registered
NGcGM3/VSSP in patients with metastatic hormone-receptor positive and HER2 negative breast cancer 28/11/2016 Registered
Racotumomab,Nimotuzumab or Docetaxel in the treatment of the advanced non-small cell lung cancer. 26/05/2014 Registered
Itolizumab Safety and Efficacy Study in Covid 19 26/03/2021 Registered
Itolizumab (T1h) combined with insulin in patients with Type I Diabetes Mellitus 23/12/2016 Registered
Phase II / III. Nimotuzumab in patients with triple-negative breast cancer. 23/05/2014 Registered
hR3 in metastatic or recurrent colorectal cancer 22/11/2013 Registered
CIMAvax-EGF in patients at high risk of lung cancer 22/10/2020 Registered
Safety and efficacy of CIMAvax®-EGF in combination with tyrosine kinase inhibitors in patients with advanced stage Non-Small Cell Lung Cancer and EGFR mutations 22/05/2021 Registered
Itolizumab for Relapsing Remitting Multiple Sclerosis 22/05/2015 Registered
NAcGM3/VSSP-aids-patients drug resistant to antiretroviral treatment-Phase I-II 22/04/2016 Registered
Preventive use of CIMAvax-EGF in patients at high risk of lung cancer. PREVAX 21/05/2021 Registered
Nimotuzumab in COVID-19 21/05/2021 Registered
EGF vaccine- Advanced Lung tumors 2013-06-20 Registered
EGF-based vaccine with VChTV Schedule in hormone-refractory prostate tumors 2013-06-19 Registered